Significance Analysis of Prognostic Signatures

PLoS Computational Biology

Volumn 9, Issue 1, 2013, Pages

  Beck, Andrew H ^a   Knoblauch, Nicholas W ^a   Hefti, Marco M ^a   Kaplan, Jennifer ^a   Schnitt, Stuart J ^a   Culhane, Aedin C ^b,c   Schroeder, Markus S ^b,c   Risch, Thomas ^b,c   Quackenbush, John ^b,c   Haibe Kains, Benjamin ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; DIAGNOSIS; DISEASES; GENE EXPRESSION;

BIOLOGICAL SIGNATURES; BREAST CANCER; CANCER METASTASIS; CANCER PROGRESSION; CANCER RESEARCH; GENE SETS; GENOMIC RESEARCH; OVARIAN CANCERS; RANDOM GENES; SIGNIFICANCE ANALYSIS;

GENOME;

ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GENETICS; CANCER PROGNOSIS; FACTUAL DATABASE; GENETIC ANALYSIS; GENETIC ASSOCIATION; OVARY CANCER; PATIENT CODING; SCORING SYSTEM; SIGNIFICANCE ANALYSIS OF PROGNOSTIC SIGNATURE SCORE; STATISTICAL ANALYSIS;

EID: 84873503854     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002875     Document Type: Article

References (32)

1. Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24: 3726.
2. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of Clinical Oncology 25: 1239.
3. Sotiriou C, Wirapati P, Loi SM, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 98: 262-272.
4. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301.
5. Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, et al. (2010) Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. Journal of Clinical Oncology 28: 1813.
6. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 5158-5165.
7. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, et al. (2011) A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast cancer research and treatment 126: 407-420.
8. Teschendorff AE, Caldas C, (2008) A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 10: R73.
9. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C, (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8: R157.
10. Weigelt B, Baehner FL, Reis Filho JS, (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. The Journal of Pathology 220: 263-280.
11. Sotiriou C, Pusztai L, (2009) Gene-Expression Signatures in Breast Cancer. N Engl J Med 360: 790-800.
12. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clinical Cancer Research 14: 5158.
13. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast cancer research: BCR 10: R65.
14. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, et al. (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. Journal of the National Cancer Institute 103: 264.
15. Venet D, Dumont JE, Detours V, (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7: e1002240.
16. Schroder MS, Culhane AC, Quackenbush J, Haibe-Kains B, (2011) survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics 27: 3206-3208.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
18. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP, (2007) GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 23: 3251-3253.
19. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) pp. 289-300.
20. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, et al. (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 104: 311-325.
21. Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, et al. (2012) Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer. PLoS One 7: e30269.
22. Haibe-Kains B, Schroeder M, Bontempi G, Sotiriou C, Quackenbush J (2011) Genefu: Relevant Functions for Gene Expression Analysis, Especially in Breast Cancer. R/Bioconductor. version: Development (2.12).
23. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, et al. (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24: 1151-1161.
24. Alibes A, Yankilevich P, Canada A, Diaz-Uriarte R, (2007) IDconverter and IDClight: conversion and annotation of gene and protein IDs. BMC Bioinformatics 8: 9.
25. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, et al. (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17: 520-525.
26. van't Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AAM, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
27. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750.
28. Chi JT, Wang Z, Nuyten DSA, Rodriguez EH, Schaner ME, et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS medicine 3: e47.
29. Buffa FM, Harris AL, West CM, Miller CJ, (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102: 428-435.
30. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, et al. (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145-1153.
31. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, et al. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
32. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, et al. (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17: 520-525.